Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Virtudes Gallardo García, Luise Goerlitz et al.|Eurosurveillance|2024Cited by 50
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studyMarine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno et al.|Influenza and Other Respiratory Viruses|2024Cited by 28
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024Charlotte Lanièce Delaunay, Esther Kissling, Aryse Melo et al.|Vaccine|2024Cited by 24
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca et al.|Influenza and Other Respiratory Viruses|2024Cited by 14
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève et al.|Eurosurveillance|2024Cited by 11